Navigation Links
As probiotics use grows for gut health, VSL#3 has designations for specific GI issues
Date:11/17/2011

GAITHERSBERG, MD, Nov. 18 As clinical studies continue to validate the use of probiotics to help promote general gastrointestinal health, a growing U.S. market1 for probiotics indicates that the U.S. healthcare community and consumers alike are recognizing the value of these beneficial microorganisms. However, because most probiotics are classified as dietary supplements, directing patients to the best probiotic for their individual needs can be challenging. And, as the category matures, one probiotic preparation -- VSL#3 -- stands apart and ahead because it is not a supplement; it has been classified as a refrigerated medical food designated for the dietary management of three major gastrointestinal conditions: Ulcerative Colitis, Ileal Pouch and Irritable Bowel Syndrome (IBS).

The World Health Organization (WHO) defines probiotics as "live microorganisms which, when administered in adequate amounts confer a health benefit to the host." But research also shows that probiotics are not "one size fits all."

"As the amount of research in the field of probiotics increases, clinical evidence continues to indicate that not all probiotics are the same; probiotic activity is strain-specific and unique, and some strains can have antagonistic or synergistic activities when mixed together," said Marc Tewey, vice president, commercial operations, at Sigma-Tau Pharmaceuticals, Inc., manufacturer of VSL#3. "VSL#3 is formulated with a precise mix of eight proprietary strains of live bacteria, and the result is a probiotic medical food so potent, it must be used under medical supervision and must be shipped and sold as a refrigerated product."

What are medical foods?

According to the FDA, medical foods are:

  • Specially formulated and processed products for the partial or exclusive feeding of a patient by means of oral intake or parenteral tube feeding
  • For dietary management of patients with special medically determined nutrient requirements that cannot be achieved by diet alone
  • Designed to provide nutritional support specifically modified for the management of the unique nutrient needs
  • Only for use under medical supervision
  • Only for a patient receiving active medical care on a recurring basis for the use of the medical food

The VSL#3 line of products contain between 112.5 billion and 900 billion live, colony-forming units (CFU), the large numbers of which make them the most potent brand of probiotics available and require the product to be refrigerated. VSL#3 utilizes a synergistic combination of diverse strains of bacteria including: Streptococcus thermophilus, Bifidobacteria longum, Bifidobacteria infantis, Bifidobacteria breve, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei and Lactobacillus delbrueckii subsp. Bulgaricus. Clinical studies using VSL#3 and published in notable journals, such as Gut, Gastroenterology and the American Journal of Gastroenterology have indicated that it colonizes the GI tract with beneficial bacteria, and in doing so, forms an intestinal barrier, which may help protect the GI tract and promote the absorption of nutrients.

"One of the main goals of physicians whose patients are living with these chronic diseases is to lengthen the periods between symptom 'flares' as much as possible," said Tewey. "Studies show that incorporating the use of this type of dietary therapy alongside traditional drug therapies can be an effective step in achieving that goal for many who suffer from these debilitating conditions."

VSL#3 is one of the few probiotic preparations supported by Level 1 (double-blind, placebo-controlled) scientific data, and has been the subject of a collection of more than 80 studies that have demonstrated its efficacy, specifically in the dietary management of IBS, Ulcerative Colitis and Ileal Pouch. It is the only probiotic recognized as an effective tool in the dietary management of pouchitis by the American College of Gastroenterology2 and by the Cochrane Review3 for the treatment and prevention of pouchtis after ileal pouch-anal anastamosis for chronic ulcerative colitis.


'/>"/>

Contact: Nicole Egan
negan@rlapr.com
914-241-0086 x28
Robin Leedy & Associates, Inc.
Source:Eurekalert

Related biology news :

1. Probiotics help gastric-bypass patients lose weight more quickly, Stanford study shows
2. Designing probiotics that ambush gut pathogens
3. A sticky solution for identifying effective probiotics
4. Probiotics help extremely premature infants gain weight
5. Probiotics, prebiotics and biofuel-producing bacteria
6. Probiotics and Health Claims
7. New polymer research could boost probiotics industry
8. NIH Clinical and Translational Science Consortium grows to 39 members
9. MIT: New tissue scaffold regrows cartilage and bone
10. Plastic that grows on trees, part two
11. Vermicompost from pig manure grows healthy hibiscus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology: